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OBJECTIVES: To assess demographic and clinical factors associated with statin
selection among patients in a large employer-based claims database. METHODS:
This study examined predictors of statin selection among statin users whowere 18
to 64 years old and initiated pravastatin (PS) vs. simvastatin (SS), atorvastatin (AS),
or rosuvastatin (RS) between 1/1/2007 and 12/31/2007. Index statin use was defined
as the first statin claim following at least 90 days of no statin access. Multiple
logistic regression models were employed to assess predictive factors of PS initia-
tion versus other statin initiations. RESULTS: Of the total 1,336,433 statin users
identified, there were 14,122 PS initiators, 66,156 AS initiators, 27,062 RS initiators,
and 77,180 SS initiators. Compared to other statin users, patients initiating PSwere
older (PS: 54.0, SS: 53.3, AS: 53.9, RS: 53.5, P0.01) and more likely to be female (PS:
52.3%, SS: 47.6%, AS: 45.4%, RS: 47.0%, P0.01). A higher percentage of PS initiators
had diabetes (PS: 20.1%, SS: 17.9%, AS: 17.9%, RS: 18.3%, P0.01), liver disease (PS:
2.7%, SS: 1.9%, AS: 2.1%, RS: 2.4%, P0.01), human immunodeficiency virus infec-
tion (HIV) (PS: 0.7%, SS: 0.1%, AS: 0.3%, RS: 0.3%, P0.01), and hypertension (PS:
45.1%, SS: 40.8%, AS: 41.1%, RS: 43.9%, P0.01) in the baseline period. After control-
ling for demographic and clinical characteristics, older age, female gender, history
of diabetes, liver disease, HIV, and hypertension were significant predictors of PS
initiation. Other predictors of PS initiation included use of calcium channel block-
ers, ezetimibe, fenofibrates, and protease inhibitors over the 1-year pre-index pe-
riod. Primary care physician (PCP) as the prescriber was positively associated with
initiating PS compared to RS or SS.CONCLUSIONS:The analyses indicate that older
age, female gender, presence of selected comorbidities, prior use of certain medi-
cations, and PCP as prescriber are predictors of PS initiation among working age,
commercially insured patients.
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OBJECTIVES: Cardiovascular diseases are the major health problem and adequate
therapy, which includes usage of beta blockers (ATC, C07) and diuretics (ATC, C03),
leads to reduction of cardiovascular morbidity andmortality. The aim of our study
was to identify and analyze changes in the usage of these drugs in Croatia and
Slovenia from 2000-2008 and to identify the rate of the generic drugs usage as well
as the average price for 1 DDD.METHODS: The data concerning consumption have
been obtained from the International Medical Statistics database for Croatia and
they are presented in defined daily doses per 1000 inhabitants per day (DDD/1000).
Financial expenditure data are presented in Euros and the average cost per DDD
was calculated for each drug group. RESULTS: The total usage of diuretics is on
average 19% higher in Croatia and continually increasing in both countries. Con-
sumption rate of furosemid among diuretics is lower in Slovenia (43.96% in 2008),
while in Croatia 67.28% (2008). The generic drugs usage is higher in Croatia during
the whole investigated period, e.g. in 2008, 87.4 % of all prescribed diuretics were
generics in Croatia, and in Slovenia 59.4%. The average price per 1 DDD was more
than twice lower in Croatia (0.08 EUR/DDD vs. 0.17 EUR/DDD in Slovenia). The beta
blockers drugs usage is 13% higher in Slovenia, but generic drugs usage is higher in
Croatia. CONCLUSIONS: Increased diuretics and beta blockers drug usage is com-
parable to worldwide trends, but drug prescribing patterns are different when
comparing both countries. Although the generic drugs usage is relatively high in
Croatia, it should be further supported and promoted. According to our investiga-
tion there is a possibility for further price reduction of diuretics and beta blockers in
Slovenia. This is important as a tool to decrease costs of healthcare systems.
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OBJECTIVES: To estimate 2003 point prevalence, treatment and control rates of
hypertension for different age groups of primary care attendees in Germany, to
examine factors associated with pharmacotherapy and adequate blood pressure
control and to examine whether changes have occurred in rates of treatment and
control since 2001. METHODS: Using standardized clinical diagnostic and treat-
ment appraisal forms, blood pressure levels and patient questionnaires for 55,518
participants from the DETECT study (2003) were analyzed. RESULTS: According to
physician diagnosis overall prevalence was 35.5%, according to NHANES criteria
56.0%. Among those defined by NHANES criteria, treatment and control rates were
56.0% and 20.3%, respectively. Significant predictors for receiving antihypertensive
medication were: increasing age, female sex, obesity, previous myocardial infarc-
tion and the prevalence of comorbid conditions such as CHD, dyslipidemia and
diabetes mellitus. Significant positive predictors of adequate blood pressure con-
trol were CHD and antihypertensive medication. Inadequate control was associ-
atedwith increasing age, male sex and obesity. As compared to findings from 2001,
rates of treatment and control indicate some improvement across all age groups.
CONCLUSIONS:Rates of treated and controlled hypertension according toNHANES
criteria in DETECT remain considerably low as compared to the rates of 2001,
despite consistent indications of some improvement. Hypertensive patients with
risk factors such as obesity and associated comorbidities such as CHD, dyslipide-
mia and diabetes weremore likely to receive antihypertensive drugs in accordance
with guidelines. Adequate blood pressure control was achieved in more patients
with obesity and CHD, but not those with diabetes mellitus or dyslipidemia.
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OBJECTIVES: To compare health care expenditures of hypertensive patients on
metoprolol tartarate (MT) andmetoprolol succinate (MS).Metoprolol, a selective -1
blocker, is available in two different salt forms in themarket-metoprolol succinate
(MS) and metoprolol tartarate (MT). Both of these salts are FDA approved for the
treatment of hypertension. Several studies have shown similar efficacies between
the two salts; however they are priced at different levels because of their pharma-
cokinetic properties. MT is the short acting salt and is given twice daily, whereas
MS is the long acting salt and is given once daily. METHODS: Two cohorts of pa-
tients usingMT andMSwere selected from 2008Medical Expenditure Panel Survey
(MEPS). Propensity score (PS) matching technique was used to balance the cohorts
on various parameters such as demographic information, insurance status and
comorbity score. Patients using MTwerematched to patients using MS on the logit
of propensity score using calipers of width equal to 0.2 of the standard deviation of
the logit of the propensity score. To estimate mean expenditure costs and 95%
confidence intervals, non parametric bootstrap sampling method was used.
RESULTS: A total of 742 patients were found to use metoprolol (MT-388, MS- 354).
After PS matching, a total of 594 patients were left in the sample for final analysis
(298 patients in each cohort). The average annual expenditure in two groups did not
differ significantly. After carrying out non parametric bootstrap sampling using
1,000 samples, MT cohort had $10,779 (95% CI: $10,682- $10,875) average annual
expenditure while MS cohort had $9,810 (95% CI: $9,810-$10,003). CONCLUSIONS:
Both the salts of Metoprolol were found have similar average annual total health-
care expenditure, however once a daily salt (MS) has higher out of pocket cost.
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OBJECTIVES: ASA/AHA guidelines for stroke prevention in patients with non-val-
vular atrial fibrillation (NVAF) recommend anticoagulant (AC) therapy with a vita-
min K antagonist (e.g., warfarin) for patients without hemorrhagic contraindica-
tion. Bridging with low molecular weight heparin (LMWH) was recently added to
these guidelines (Class IIa), butwith little supportive evidence (Level of Evidence C).
Little is known about the use of AC therapy in the inpatient setting and how it
relates to hospital length of stay (LOS).METHODS: Patientswith anNVAF discharge
diagnosis between 7/1/04-9/30/09 were identified from administrative claims data
representing over a hundred US hospitals. Inpatient AC use by drug type was re-
ported to identify patients receiving warfarin alone and in combination with
LMWH/pentasaccharide (PS) or unfractionated heparin (UFH), indicative of bridg-
ing. LOS was measured and reported by AC combinations. Non-parametric statis-
tical tests were used to compare LOS among patients receiving warfarin only to
thosewith bridge therapy.RESULTS:Of 6340NVAFpatients, 76% received inpatient
AC therapy, with 3037 (48%) receiving warfarin. Of patients receiving warfarin, 64%
were bridged with another AC. LMWH/PS was themost common bridge agent (45%
of all bridged patients), followed byUFH (36%), and by LMWH/PS andUFH combined
(18%). The mean LOS for patients receiving bridge therapies was 6.3 days (SD6.1)
compared to 4.2 days (SD 3.1) for warfarin alone, p.0001. By bridging drug type,
mean LOS was 5.6 days (SD5.3) for LMWH/PS; 6.0 days (SD4.9) for UFH, and 8.4
days (SD8.4) for LMWH/PS and UFH. CONCLUSIONS: Less than half of all NVAF
patients receivedwarfarinwhile hospitalized. Among those takingwarfarin, bridg-
ing with other anticoagulants was common and was associated with longer LOS
than patients receiving warfarin alone.
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OBJECTIVES: Electronic Medical Records often lack accurate problem lists. The
objectives of this studywere to examine if alerts requesting indication information
during order entry of medications used to treat a common disease, hypertension,
can improve problem lists. METHODS: Inpatient orders generated by previously
implemented clinical decision support (CDS) in an academic hospital using CPOE
were reviewed. CDSwas developed for classes of antihypertensive and 3 additional
diagnoses: CHF, benign prostatic hypertrophy and nephropathy. Five logical med-
ication groups were developed. A random sample of 250 charts were collected for
each medication group and reviewed by physicians to determine alert yield and
added problem accuracy. The accuracy and yield (problems added per order) were
analyzed across the medication groups, clinician types, and clinical venues.
RESULTS: Preliminary results obtained from the group of medications that only
treat HTN and no other diagnoses (HTN group) showed an accuracy of additions to
the problem list of 92% and the yield, was 76%. For the group of medications which
treated HTN and CHF (CHF group), the accuracy and yield were lower, 81% and 62%
respectively. Looking at the HTN group alone, the accuracy was 100% for attending
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